OpGen (NASDAQ:OPGN) Earns Sell Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of OpGen (NASDAQ:OPGN) in a research report sent to investors on Monday. The brokerage issued a sell rating on the medical research company’s stock.

OpGen Stock Performance

OPGN stock opened at $1.54 on Monday. OpGen has a 1-year low of $1.40 and a 1-year high of $9.90. The business has a 50 day simple moving average of $1.79 and a two-hundred day simple moving average of $2.37.

About OpGen

OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.